COMP <GO>
INMD vs ABBV // PIOTROSKI F-SCORE QUALITY
InMode Ltd. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INMD 4
— ABBV 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: ABBV
LAST: $13.51 (+1.05%) • MKT CAP: $776.6M
piotroski-score
4/9
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.50% | 70.20% | +8.30 | INMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.70% | 29.00% | -11.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | 33.3x | -27.80 | INMD | /valuation <GO> |
| Free Cash Flow Yield | 10.85% | 3.47% | +7.38 | INMD | /fcf-yield <GO> |
| Operating Margin | 23.00% | 24.60% | -1.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | — | 6.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -6.20% | 8.60% | -14.80 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.20 | 5.33 | +3.87 | INMD | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.3 | 65.1 | -28.80 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $776.6M | $513.86B | -$513.08B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INMD REV | ABBV REV | INMD GROSS % | ABBV GROSS % | INMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $370.5M | $61.16B | 78.5% | 70.2% | $84.3M | $17.82B |
| FY 2024 | $394.8M | $56.33B | 80.3% | 70.0% | $132.0M | $17.83B |
| FY 2023 | $492.0M | $54.32B | — | — | $176.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INMD // BETA —
ABBV // BETA 1.15